STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
Woelfel S, Dütschler J, König M, Dulovic A, Graf N, Junker D, Oikonomou V, Krieger C, Truniger S, Franke A, Eckhold A, Forsch K, Koller S, Wyss J, Krupka N, Oberholzer M, Frei N, Geissler N, Schaub P; STAR SIGN Study Investigators; Albrich WC, Friedrich M, Schneiderhan-Marra N, Misselwitz B, Korte W, Bürgi JJ, Brand S.
Woelfel S, et al. Among authors: koller s.
Aliment Pharmacol Ther. 2023 Oct;58(7):678-691. doi: 10.1111/apt.17661. Epub 2023 Aug 12.
Aliment Pharmacol Ther. 2023.
PMID: 37571863